Abstract Details

Title Motor Neuron Disease: Cellular or Molecular Experimental Therapy. What Works Better?

Topic General Neurology

Presentation(s) P8 - Poster Session 8 (8:00 AM-9:00 AM)

Poster/Presentation
Number 6-003

Objective Amyotrophic lateral sclerosis (ALS) as a variation of a motor neuron diseases is a chronic, disabling and untreatable neurodegenerative disease. The main symptom is atrophy of sceletal muscles including respiratory intervetebral muscles. There is no effective treatment of this condition. Experimental therapy of ALS animal model including cellular and molecular approaches seems interesting and promiseable in terms of development of new cure of this severe disease.

Background The transplantation of genetically modified cells (stem, precursors, differentiated) is actively studied as a way of delivering growth factors and adhesion molecules to damaged nerve tissue to maintain the viability of neurons, ensure regeneration of nerve processes and restore lost cell-to-cell contacts. In the present study, for treatment of ALS in the transgenic mouse model, we constructed the plasmid vector pBud-VEGF-L1CAM.

Design/Methods SOD1G93A mice were used for ALS model in human patients. 24 mice received chemokine (C-X3-C motif) ligand 1 (CX3CL1), which mediates microglial activation. 21 experimental animals were treated by injecting of human induced pluripotent stem cells (hiPSCs) into CSF, sceletal muscles in spinal cords. First control group cosisted from 34 healthy mice did not receive any therapy. Second control group consisted from SOD1G93A mice also did not receive any treatment. Electromyography was performed in experimental mice and in control group of healthy mice.

Results Significant impact of both cellular and molecular treatment in both experimental SOD1G93A mice ALS symptoms improvement, mostly locomotor activity. On same time, muscular athrophy was decreased mostly in result of SOD1G93A mice were used for ALS model in human patients. Electromyography showed consideralble improvement of muscular activity.

Conclusions

Future treatment of ALS/MND symptoms has include both cellular and molecucular approaches. Stem cell therapy would include both cellular and molecular approaches by inoculating these substances into ALS patients body. Electromyography could be used as valuable indicator of ALS animal models experimental treatment.

Authors/Disclosures
Dmitriy Labunskiy (Ogarev Mordovia State University) PRESENTER	Mr. Labunskiy has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details